KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$11.30 USD
+0.01 (0.09%)
Updated May 24, 2024 04:00 PM ET
After-Market: $11.31 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 61 - 80 ( 105 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Anticipated COVID-19 Delays Could Have Minimal Impact
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our Presenting Companies at the ROTH Conference and 2020 Catalyst Calendar
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our Presenting Companies at the ROTH Conference and 2020 Catalyst Calendar
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Merck Option to DME Program Expires, KalVista to Determine Next Steps
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
On-Demand HAE Study Data in 2Q20 - Prophylactic HAE Study Start in 2H20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
HAE Study to Readout During 2020, but DME Study Remains on Deck for 4Q19.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Eying the Potential of KalVista?s KVD001 in Diabetic Macular Edema
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY1Q Update - With Two Shots on Goal by YE2019, We''re Liking Our Odds
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z